Cargando…

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

BACKGROUND: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of gastric emptying. We examined the potential of GLP-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behme, Margaret T, Dupré, John, McDonald, Thomas J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154101/ https://www.ncbi.nlm.nih.gov/pubmed/12697069 http://dx.doi.org/10.1186/1472-6823-3-3

Ejemplares similares

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
por: Salehi, Marzieh, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
por: Jia, Guanghong, et al.
Publicado: (2016)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
por: Larsen, Matthias Ploug, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
por: Guo, Keyu, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes
por: Risovic, Ivona, et al.
Publicado: (2023)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Methylation status of vault RNA 2-1 promoter is a predictor of glycemic response to glucagon-like peptide-1 analog therapy in type 2 diabetes mellitus
por: Lin, Chia-Hung, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
por: Su, Haoran, et al.
Publicado: (2008)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis
por: Kim, Hyeonhui, et al.
Publicado: (2018)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Li, Zhixia, et al.
Publicado: (2016)

Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
por: Kim, Pyung-Hwan, et al.
Publicado: (2012)

Glucagon−like Peptide−1 and−2 Levels in Children with Diabetic Ketoacidosis
por: Akıncı, Ayşehan, et al.
Publicado: (2009)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney, Hamish, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5fatfeomnpicnjtn291ok89fmk